1. Home
  2. CLPS vs BTAI Comparison

CLPS vs BTAI Comparison

Compare CLPS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

HOLD

Current Price

$0.88

Market Cap

36.0M

Sector

Technology

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.14

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
BTAI
Founded
2005
2017
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0M
35.6M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
CLPS
BTAI
Price
$0.88
$1.14
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
10.5K
882.4K
Earning Date
03-06-2026
05-11-2026
Dividend Yield
14.86%
N/A
EPS Growth
N/A
75.63
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$141.28
Revenue Next Year
N/A
$1,921.56
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$1.08
52 Week High
$1.88
$8.08

Technical Indicators

Market Signals
Indicator
CLPS
BTAI
Relative Strength Index (RSI) 28.91 32.20
Support Level $0.83 N/A
Resistance Level $0.96 $1.77
Average True Range (ATR) 0.04 0.12
MACD -0.01 -0.03
Stochastic Oscillator 6.72 8.21

Price Performance

Historical Comparison
CLPS
BTAI

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: